Dyes for Your Near-Infrared Imaging Needs
LI-COR Clinical Translation
seeks to facilitate the use of IRDye® 800CW imaging agents in clinical studies for detection of disease and its progression, and for monitoring of treatment and drug efficacy
IRDye 800CW is ideal for protein and antibody labeling, or nucleic acid applications with high labeling density.
Optimal performance in Western blotting and immunocytochemical assays
Superior performance for in vivo imaging
High water solubility and salt tolerance
Low nonspecific binding to cellular components
High signal-to-noise ratio
LI-COR Clinical Translation seeks to facilitate the use of IRDye 800CW imaging agents in clinical studies for detection of disease and its progression, and for monitoring of treatment and drug efficacy.
Used by leading molecular imaging laboratories that develop translatable targeting agents
Easily conjugated to biomolecules (unlike ICG, which cannot be attached to biomolecules in its clinically approved form)
To discuss commercial development rights using IRDye infrared dyes, please contact Business Development.
IRDye near-infrared dyes are optimized for excitation and detection in the near-infrared spectrum,
providing numerous benefits.
Advantages of IRDye® near-infrared dyes:
low background autofluorescence
higher signal-to-noise ratios
Higher signal-to-noise ratios with near-infrared fluorescence Westerns
True multiplex Western blot detection requires high sensitivity in BOTH fluorescent channels.
Infrared fluorescence: Detect endogenous protein levels in both channels
Visible fluorescence: Insufficient sensitivity in one channel
ERK1/2 and phospho-ERK were detected in lysates of unstimulated or EGF-stimulated A431 cells. Two-fold serial dilutions of lysate were loaded. Replicate blots were detected using ERK1/2 or phospho-ERK primary antibodies and secondary antibodies labeled with infrared or visible fluorescent dyes.
When autofluorescent background is low:
Tumors are more easily detected
Tumor-to-background ratio is increased
IRDye® 800CW optical probes provide excellent performance for in vivo imaging.
Mice with MDA-MB-468 tumors were injected with 1 nmol of IRDye 800CW - EGF or Cy 5.5 - EGF optical probe. Animals were imaged 24 h after injection.
A) IRDye 800CW - EGF probe
Tumor is easily visualized (red circle)
B) Cy 5.5 - EGF probe
Tumor is difficult to detect
The IRDye 800CW EGF imaging probe yielded a 5.8-fold improvement in tumor-to-background ratio,
compared to Cy 5.51
1. Adams et al. J Biomedical Optics, 12(2), 024017 (2007)
IRDye 800CW Dye Products
IRDye 800CW Conjugates
September 10, 2007: LINCOLN, Neb. – LI-COR® Biosciences announces successful completion of animal toxicity studies of its IRDye® 800CW infrared dye carboxylic acid using a protocol reviewed by the Food and Drug Administration. The completion of the toxicity studies is a key milestone in the development of the IRDye 800CW dye for potential clinical imaging use.
LI-COR IRDye infrared fluorescent dyes are used for protein and cellular assays, microscopy, and in vivo molecular imaging in animals for research purposes. IRDye 800CW is cited in a wide variety of published non-clinical research for labeling nucleic acids, antibodies, proteins, and peptides where there is a need for high signal, low background imaging. With an 800 nm emission wavelength, the IRDye 800CW dye is spectrally ideal for animal imaging research.
For more than 16 years scientists have used LI-COR infrared dyes for research including drug discovery, cell signaling analysis, animal imaging, and the Human Genome Project. LI-COR develops instrumentation, analysis software, and infrared reagents offering researchers a complete solution for protein analysis, genomics, and animal imaging.
“The unique characteristics of the IRDye 800CW infrared dye make it an excellent choice for molecular and small animal research,” says Jeff Harford, LI-COR product manager. “Completing the animal toxicity studies is the logical next step in the development of the IRDye 800CW infrared dye for use in the clinical setting and is critical to our preparation for future clinical investigations.”
While the IRDye 800CW dye has successfully completed toxicity studies, it has not been studied for diagnostic or therapeutic use in humans, and has not been approved by the Food and Drug Administration for this use. LI-COR is exploring options for additional studies as next steps in the Food and Drug Administration approval process leading toward clinical use.